A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumours

Titre officiel

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081, in Subjects With Advanced Stage Solid Tumours

Sommaire:

The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.

Description de l'essai

Primary Outcome:

  • Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
  • Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
  • Part 1: Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Secondary Outcome:
  • Part 1 and Part 2: Serum Concentrations of JNJ-63898081
  • Part 1 and 2: Systemic Cytokine Concentrations
  • Part 1 and 2: Concentration of Markers of T-Cell Activation
  • Part 1 and 2: Number of Participants with JNJ-63898081 Antibodies
  • Serum Prostate Specific Antigen (PSA) Concentration
  • Percentage of JNJ-63898081 Receptor Occupancy

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer